‘For a few unknown reason, it’s been incredibly difficult to replicate the symptoms of Parkinson’s in mice, even though presenting in the genome of the pets the same mutations within humans suffering from familial forms of the condition. Our discovery offers a new result in potentially overcome such complications’ Trudeau explained. Improved pet models open a number of fresh avenues of research. ‘It is possible that new medicines could be developed to greatly help the neurons involved reduce their energy usage or produce energy better, which would decrease accumulated damage over the entire years,’ Trudeau said.This is a larger clinical research with a far more mixed population,’ Reilly explains. The Stage III trial may be the final hurdle within an approval process that may consider 10 years or even more alltogether. One expert believes the task is quite challenging. ‘In this task they humanised a mouse monoclonal antibody. ‘It could trigger a secondary effect not observed in vitro or in mice. Therefore sometimes that could be a headaches or fever or something similar to that. At the biological level there are variations between a mouse model and human, so I think that is quite an interesting project.